<SEC-DOCUMENT>0001395064-21-000053.txt : 20210406
<SEC-HEADER>0001395064-21-000053.hdr.sgml : 20210406
<ACCEPTANCE-DATETIME>20210406060557
ACCESSION NUMBER:		0001395064-21-000053
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210406
DATE AS OF CHANGE:		20210406

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phathom Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001783183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824151574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91182
		FILM NUMBER:		21808051

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(877) 742-8466

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TAKEDA PHARMACEUTICAL CO LTD
		CENTRAL INDEX KEY:			0001395064
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-8668
		BUSINESS PHONE:		81332782111

	MAIL ADDRESS:	
		STREET 1:		1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-8668
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>sc13da-040621.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibc86642d0ebf47cfada0955a6e3195b6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:39.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WASHINGTON, DC  20549</font></div><div style="text-align:center"><font><br></font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCHEDULE 13D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Rule 13d-101)</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Amendment No. 3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phathom Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name of Issuer)</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock, $.0001 par value</font></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Title of Class of Securities)</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71722W107</font></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(CUSIP Number)</font></div><div style="margin-bottom:0.03pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1-1, Nihonbashi-Honcho 2-Chome</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chuo-ku, Tokyo 103-8668, Japan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Attn&#58; Yoshihiro Nakagawa</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tel&#58; +81-3-3278-2111 </font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With a copy to&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Davis Polk &#38; Wardwell LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">450 Lexington Avenue</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New York, NY 10017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Attention&#58; William J. Chudd</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tel&#58; (212) 450-4089</font></div><div><font><br></font></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name, Address and Telephone Number of Person<br>Authorized to Receive Notices and Communications)</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">April 2, 2021</font></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Date of Event Which Requires Filing of This Statement)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.    </font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rule 13d-7 for other parties to whom copies are to be sent.</font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The information required on the remainder of this cover page shall not be deemed to be &#34;filed&#34; for the purpose of Section 18 of the Securities Exchange Act of 1934 (&#34;Act&#34;) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> see</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="ibc86642d0ebf47cfada0955a6e3195b6_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CUSIP No.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">71722W107</font></div></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:5.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NAME OF REPORTING PERSON</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S.S. OR I.R.S. IDENTIFICATION NO. (VOLUNTARY)</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20pt;padding-right:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda Pharmaceutical Company Limited</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#91; &#93;</font></div><div style="margin-bottom:2.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) &#91; &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></div></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC USE ONLY</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOURCE OF FUNDS</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;padding-right:34.5pt;text-align:right;text-indent:7.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OO</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font></div></td><td colspan="9" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CITIZENSHIP OR PLACE OF ORGANIZATION</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt;padding-right:34.5pt;text-align:right"><font><br></font></div><div style="margin-bottom:2.9pt;padding-right:34.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Japan</font></div></td></tr><tr style="height:36pt"><td colspan="6" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOLE VOTING POWER</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right;text-indent:7.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,672,000*</font></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHARED VOTING POWER</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:2.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;0</font></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOLE DISPOSITIVE POWER</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right;text-indent:7.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,672,000*</font></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHARED DISPOSITIVE POWER</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right"><font><br></font></div><div style="margin-bottom:2.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0  </font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON </font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,672,000*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font></div></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXCLUDES CERTAIN SHARES</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right"><font><br></font></div><div style="margin-bottom:2.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.3%**</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TYPE OF REPORTING PERSON</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;text-align:right"><font><br></font></div><div style="margin-bottom:2.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CO</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Includes 7,588,000 shares issuable upon exercise of a Warrant to purchase Common Stock.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Based on 31,321,613 shares of Common Stock outstanding as of March 26, 2021, as reported in the Issuer&#8217;s Report on Form 10-K for the period ended December 30, 2020 filed with the Securities and Exchange Commission on March 30, 2021, and giving effect to the exercise in full of the Warrant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ibc86642d0ebf47cfada0955a6e3195b6_74"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CUSIP No.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">71722W107</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 3 TO SCHEDULE 13D</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment No. 3 (&#8220;Amendment No. 3&#8221;) amends the statement on Schedule 13D (as amended, the &#8220;Schedule 13D&#8221;) filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) by the Reporting Person with respect to the Common Stock of the Issuer on November 6, 2019, and as further amended by Amendment No. 1 filed with the SEC on January 27, 2020 and by Amendment No. 2 filed with the SEC on April 1, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following items of the Schedule 13D are amended as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;  Purpose of Transaction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Item 4 is hereby supplemented with the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On April 2, 2021, the Reporting Person entered into a stock trading plan with Nomura Securities International, Inc. (&#8220;Nomura&#8221;) pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;10b5-1 Plan&#8221;). The description of the 10b5-1 Plan set forth in Item 6 below is incorporated herein by reference in its entirety.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The transactions contemplated by the 10b5-1 Plan will result in the disposition of securities of the Issuer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;  Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Item 6 is hereby supplemented with the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">10b5-1 Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 10b5-1 Plan, Nomura may sell up to 1,084,000 shares of Common Stock owned by the Reporting Person. All sales under the 10b5-1 Plan are to be made in the discretion of Nomura and in accordance with the terms, conditions and restrictions of the 10b5-1 Plan. Pursuant to the 10b5-1 Plan, sales will commence on May 3, 2021 and will continue until August 31, 2021 or until all of the shares of Common Stock to be sold under the 10b5-1 Plan are sold or the 10b5-1 Plan is otherwise terminated.  A copy of the 10b5-1 Plan is attached as Exhibit D hereto and incorporated herein by reference.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;Material to Be Filed as Exhibits.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Item 7 is hereby supplemented with the following&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Exhibit D&#58; 10b5-1 trading plan between Nomura Securities International, Inc. and Takeda Pharmaceutical Company Limited, dated April 2, 2021 (filed herewith).</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="ibc86642d0ebf47cfada0955a6e3195b6_85"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CUSIP No.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">71722W107</font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">After reasonable inquiry and to the best of the undersigned&#8217;s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</font></div><div style="text-indent:45pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;  April 6, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TAKEDA PHARMACEUTICAL COMPANY LIMITED </font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Amit Singh                                        </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Amit Singh</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Senior Vice President and Treasurer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="ibc86642d0ebf47cfada0955a6e3195b6_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit D&#58; 10b5-1 trading plan between Nomura Securities International, Inc. and Takeda Pharmaceutical Company Limited, dated April 2, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="ibc86642d0ebf47cfada0955a6e3195b6_99"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:24px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.228%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #6d6d6d;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nomura Securities International, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">309 West 49th Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:118%">New York, NY 10019</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:121%">(212) 667-9000</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">April 2, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Re&#58; Written Plan for the Sale of Securities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This letter agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is intended by Seller to create a written plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for the sale of common shares, par value $0.0001 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), of Phathom Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Issuer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in accordance with Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Accordingly, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Seller hereby instructs Nomura Securities International, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nomura</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to effect sales of Shares in accordance with the instructions set out on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Seller shall pay Nomura the Commission Amount specified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, with such amounts to be deducted by Nomura from the proceeds of sales under this Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Seller represents, warrants and covenants to Nomura that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;it is not entering into this Letter Agreement on the basis of any material non-public information regarding the Issuer or the Shares.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;it is entering into this Letter Agreement in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 or any other provision of any applicable federal, state or foreign securities laws or regulations.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;it is the intent of the Parties that this Letter Agreement and this Plan comply with (and be interpreted to comply with) the requirements of paragraph (c)(1)(i) of Rule 10b5-1.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(d)&#160;&#160;&#160;&#160;it will not seek to influence Nomura&#8217;s decision over how, when, or whether to effect any &#8220;purchases or sales&#8221; (within the meaning of Rule 10b5-1(c)(1)(i)(B)(3)) in connection herewith.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e)&#160;&#160;&#160;&#160;it will not enter into or alter a corresponding or hedging transaction or position with respect to the Shares.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(f)&#160;&#160;&#160;&#160;it has obtained such legal or other advice as it deems appropriate regarding the legal aspects of its adoption and implementation of this Plan under Rule 10b5-1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(g)&#160;&#160;&#160;&#160;it has informed the Issuer of this Plan and has furnished the Issuer with a copy, and it has determined that entry into this Letter Agreement complies with all internal policies of the Issuer applicable to Seller and its affiliates.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(h) &#160;&#160;&#160;&#160;it is not subject to any legal, regulatory or contractual restriction or undertaking that would prevent Nomura from conducting sales in accordance with this Plan.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(i) &#160;&#160;&#160;&#160;the Shares to be sold under this Plan are owned free and clear by it and are not subject to any liens, security interests or other encumbrances or limitations on dispositions, other than those imposed by Rule 144 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) under the Securities Act, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and are held in book-entry form with The Depositary Trust Company.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(j)&#160;&#160;&#160;&#160;it will  make all filings, if any, required under Sections 13(d), 13(g) and 16 of the Exchange Act in a timely manner, to the extent any such filings are applicable to it.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(k)&#160;&#160;&#160;&#160;the Shares to be sold pursuant to this Plan are currently eligible for sale under Rule 144.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(l) &#160;&#160;&#160;&#160;until this Plan has been terminated, it will not (i) enter into a binding contract with respect to the purchase or sale of Shares with another broker, dealer or financial institution (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) or any other person, (ii) instruct another Financial Institution to purchase or sell Shares or (iii) adopt a plan for trading with respect to Shares other than this Plan&#59; provided, however, that the restriction under this clause (l) shall not apply to any shares described in paragraph (e)(3)(vii) of Rule 144.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(m)&#160;&#160;&#160;&#160;it will not take, nor permit any person or entity with which it would be required to aggregate sales of Shares pursuant to paragraph (a)(2) or (e) of Rule 144 not to take, any action that would cause the sales hereunder not to meet all applicable requirements of Rule 144.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(n)&#160;&#160;&#160;&#160;it will complete, execute and deliver to Nomura a Rule 144 Representation Letter (in the form attached as Exhibit B) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Rule 144 Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) for sales to be effected under this Plan.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(o)&#160;&#160;&#160;&#160;it will complete and file any Forms 144 required to be filed in connection with sales of Shares hereunder.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(p)&#160;&#160;&#160;&#160;any amendment, modification, waiver or termination of this Letter Agreement or this Plan must be effected in accordance with the requirements for the amendment or termination of a &#8220;plan&#8221; under Rule 10b5-1(c).&#160; Without limiting the generality of the foregoing, any such amendment, modification, waiver or termination shall be made in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5, and no such amendment, modification, waiver or termination shall be made at any time at which Seller is aware of any material non-public information regarding the Issuer or the Shares.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;This Letter Agreement, including this Plan, shall terminate on the earliest to occur of&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;the date on which the aggregate amount of Shares covered by this Plan have been sold.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Scheduled End Date specified on Exhibit A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;the date on which Seller notifies Nomura as specified hereunder and in compliance with the provisions of Rule 10b5-1 and all other applicable securities laws that this Plan is terminated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;a reasonable determination by Nomura that&#58; (i) this Plan does not comply with Rule 10b5-1 or other applicable securities laws or (ii) Seller has not complied with the terms of this Plan, Rule 10b5-1 or other applicable securities laws.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the filing of a bankruptcy petition by the Issuer&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the public announcement of a merger, recapitalization, acquisition, tender or exchange offer, or other business combination or reorganization resulting in the exchange or conversion of the Issuer&#8217;s common shares into securities of a company other than the Issuer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the conversion of the Issuer&#8217;s common shares into rights to receive fixed amounts of cash or into debt securities and&#47;or preferred stock or other securities (whether in whole or in part).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;(a)  Any notice to Seller required or permitted by this Letter Agreement will be deemed sufficient if mailed, e-mailed, or delivered to the following address&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Takeda Pharmaceutical Company Limited</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Global Finance &#8211; Treasury Operations APAC &#38; Japan &#8211; Treasury</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; Paula Rebelo</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-1, Nihonbashi-Honcho 2-chome</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chuo-ku, Tokyo, Japan </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">email&#58; *** REDACTED ***</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)  Any notice to Nomura required or permitted by this Letter Agreement will be deemed sufficient if mailed, e-mailed, or delivered to the following address&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nomura Securities International, Inc.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">World Wide Plaza</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">309 West 49th Street</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">New York, NY 10019</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">email&#58;  *** REDACTED ***</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;(a)  Seller agrees to indemnify and hold harmless Nomura and its directors, officers, employees and affiliates from and against all claims, losses, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) arising out of or attributable to (a) Nomura&#8217;s actions taken or not taken in compliance with this Plan, (b) any breach by Seller of this Plan (including Seller&#8217;s representations and warranties hereunder or in the Rule 144 Letter), or (c) any violation by Seller of applicable laws or regulations. This indemnification shall survive termination of this Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)  Notwithstanding any other provision hereof, Nomura shall not be liable to Seller for&#58; (i) special, indirect, punitive, exemplary or consequential damages, or incidental losses or damages of any kind, even if advised of the possibility of such losses or damages or if such losses or damages could have been reasonably foreseen&#59; (ii) any failure to perform or to cease performance or any delay in performance that results from a cause or circumstance that is beyond its reasonable control, including, but not limited to, failure of electronic or mechanical equipment, strikes, failure of common carrier or utility systems, severe weather, market disruptions or other causes commonly known as &#8220;acts of God&#8221;.  In addition, Nomura shall not be liable to Seller for (x) the exercise of discretionary authority or discretionary control </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under this Plan, if any or (y) any failure to effect a sale required by Section 1, except for failures to effect sales that are a direct result of the gross negligence or willful misconduct of Nomura.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">7.&#160;&#160;&#160;&#160;With respect to any suit, action or proceedings relating to any dispute arising out of or in connection with this Letter Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), Seller irrevocably submits to the exclusive jurisdiction of the courts of the State of New York and the United States District Court located in the Borough of Manhattan in New York City and waives any objection which it may have at any time to the laying of venue of any Proceedings brought in any such court, waives any claim that such Proceedings have been brought in an inconvenient forum and further waives the right to object, with respect to such Proceedings, that such court does not have any jurisdiction over Seller. EACH PARTY HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY PROCEEDINGS.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">8.&#160;&#160;&#160;&#160;This Letter Agreement constitutes the entire agreement and understanding of the parties with respect to its subject matter and supersedes all oral communication and prior writings with respect thereto. No amendment, modification or waiver in respect of the matters contemplated by this Letter Agreement will be effective unless in writing and executed by each of the parties.  This Letter Agreement may be executed and delivered in counterparts (including by facsimile or email transmission), each of which will be deemed an original. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature page follows&#93;</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Letter Agreement shall be construed in accordance with, and this letter and all matters arising out of or relating in any way whatsoever to this letter (whether in contract, tort or otherwise) shall be governed by, the law of the State of New York.  </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Please indicate your agreement to the foregoing by executing this Letter Agreement and returning it to Nomura.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Sincerely,</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">NOMURA SECURITIES INTERNATIONAL, INC.</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; James A. Chenard</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Name&#58; James Chenard</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Title&#58; Managing Director</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">ACCEPTED AND AGREED, as Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#58;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Takeda Pharmaceutical Company Limited</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; Amitabh Singh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Name&#58; Amitabh Singh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Title&#58; SVP Group Treasurer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01a.jpg
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M6UR@.IFOU]\;>8HR&?X^'HW#/QS',<(%ZICE\OLR(4W[3,:_3T;AO>,X^KA
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MVHK:>[\A3P*L3]>2QIPT-N-$DRD=DZL+5%]!>7VC>)I((_(6N.;%SH+'Y 6
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M;HN(O$4:DZM9*$7+FMU;)#=00J F:"]99J$,I_SA8(V@#X$R#<JQV26459$
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MEAL]UC&BYR VB3/*&.]C;[Y]GPO.UFCR2>LV-/)@[R.[2N!3$HYD^@0(CK8
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5?PLV5G6]@,SK     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
